(BCCEF) Completes Debt Conversion

TORONTO, CANADA–(Aug. 29, 2014) – BacTech Environmental Corporation (“BacTech”) (CSE:BAC)(OTC:BCCEF)(WKN:A1H4TY) today announced that its $600,000 Bridge Loan (issued July 2013) and the $585,000 Debenture (issued May 2012), plus the accrued interest to July 31 2014, have been converted to 27,742,934 common shares at a price of $0.05 per common share. The Company has also converted $115,000 of debt owing to management and consultants, to 2,300,000 common shares at the same price. In total, $1,502,000 of debt and accumulated interest has been converted to 30,042,934 common shares. Following this transaction, the Company has manageable debt outstanding.

As a result of the conversion, Option Three Advisory Services Limited, the Company’s largest shareholder, will increase its interest in BacTech to 16,549,267 common shares or 39.9% of the outstanding common shares. In addition, Philip Richards, a resident of London, England will own 4,280,000 common shares or 10.3% of the Company.

As a result of the conversion BacTech will have 41,393,944 common shares issued and outstanding and 46,673,877 common shares fully diluted.

BacTech Profile

BacTech Environmental Corporation holds the perpetual, exclusive, royalty-free rights to use the patented BACOX bioleaching technology for the reclamation of tailings and mining waste materials. BacTech signed a contract with the Mines Branch of the Manitoba Department of Innovation, Energy and Mines, to remediate an arsenopyrite gold stockpile situated at the Snow Lake Mine in Snow Lake, Manitoba. The project is presently on hold. A second high-grade silver/copper project is under negotiation at Atocha, Bolivia in partnership with COMIBOL, the state mining group. The Company continues to field enquiries globally with respect to additional opportunities for remediation including licensing transactions for the technology.

Special Note Regarding Forward-Looking Statements

This news release contains “forward-looking information”, which may include, but is not limited to, statements with respect to future tailings sites, sampling or other investigations of tailing sites, the Company’s ability to make use of infrastructure around tailings sites or operating performance of the Company and its projects. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward- looking statements.

Shares outstanding 41,393,944

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

BacTech Environmental Corporation
Ross Orr
President & CEO
416-813-0303 ext 222
info@bactechgreen.com

BacTech Environmental Corporation
Bill Mitoulas
Investor Relations
416-479-9547
bmitoulas@bactechgreen.com
www.bactechgreen.com

(RSH) Joins Forces with RadioShack to Launch New Military Focused Mobile Service

RadioShack to be the exclusive national retailer for Defense Mobile’s 4G LTE services for active military service members, veterans and their families

FORT WORTH, Texas and WESTPORT, Conn., Aug. 28, 2014  — RadioShack and Defense Mobile Corporation announced today that the companies have entered into an agreement for RadioShack to be the exclusive national retailer for Defense Mobile’s new nationwide 4G LTE mobile services.

Built by veterans and supported by a 100 percent veteran-staffed Member Service organization, Defense Mobile is launching nationwide mobile services and a set of value-added applications that are designed to benefit, honor and reward active U.S. military and veterans for their commitment and service.

RadioShack will begin offering Defense Mobile’s branch branded mobile services exclusively to the 51.6 million members of the U.S. military community, including those actively serving (including members of the Reserve and National Guard), veterans and their family members, planned for Sept.

Defense Mobile brands, including ARMYmobile, NAVYmobile, AIRFORCEmobile, MARINESmobile and COASTGUARDmobile, will be offered initially in 2,500 RadioShack stores, and all company locations by 2015.

Defense Mobile has established partnerships with the nation’s fastest, most reliable and largest network operators in order to deliver superior nationwide 4G mobile services to its members. Additionally, the company has partnered with the largest device manufacturers and will offer financing options on the most popular smartphones to eligible customers at RadioShack stores.

“RadioShack stores are located in the heart of communities where veterans work and live,” said Brendan Reilly, chief executive officer at Defense Mobile Corporation. “We are excited that RadioShack is committed to our mission to connect and improve the lives of veterans.”

“At RadioShack, we know the importance of connecting veterans and those serving in the military with their loved ones. We feel honored to add the complete line of Defense Mobile services to our mobility offerings,” said Paul Rutenis, chief merchandising officer at RadioShack. “We have long offered a 10 percent discount to military families and launching Defense Mobile is one more way we can provide custom offerings to these loyal consumers.”

Added Benefits of Defense Mobile

After an in-store validation of military service, Defense Mobile provides value-added applications delivered directly to the mobile device and its Members. The pre-loaded or downloadable applications available at launch include: MiliCASH, a robust mobile banking application with a pre-approved prepaid MasterCard that delivers military-and-veteran-only cash back rewards at participating merchants nationwide and MiliSOURCE, a powerful application that helps veteran families discover and obtain valuable veteran benefits and services from the VA, States, and Veteran Service Organizations. Additionally Members receive MiliMAIL, a free email service providing transitioning military personnel and Defense Mobile Members with a unique email that proudly confirms their affiliation to the branch of service they served.

About RadioShack Corporation

RadioShack (NYSE: RSH) is a leading retailer with more than 27,000 knowledgeable associates focused on connecting consumers with personalized solutions and discovering what’s possible through the latest in consumer electronics. The company’s updated product assortment incorporates national brands, industry-leading private brand products, mobile devices and wireless carriers. Customers can shop leading brands in headphones and speakers, wearable technology, smart toys and DIY supplies, connected home, power accessories and home entertainment at www.radioshack.com, or at one of the more than 5,000 locations in 26 countries. Find RadioShack on Facebook, Twitter, Instagram, and YouTube.

About Defense Mobile Corporation

Defense Mobile Corporation (DMC) provides mobile services, smartphones, and apps for active duty military, veterans and their families.  Defense Mobile is a new nationwide 4G mobile service, built by veterans, supported exclusively by veterans and designed to improve the lives of those who have served. Defense Mobile offers the most popular smartphones, no annual contract plans, meaningful “military and veteran only” cash back rewards, and applications that help veterans manage the benefits they have earned. Defense Mobile has secured agreements to run on the largest mobile network operators so that veterans and military families receive superior coverage. You can learn more about Defense Mobile Corporation at www.defensemobile.com or the service brands at armymobile.com, navymobile.com, airforcemobile.com, marinesmobile.com, and coastguardmobile.com.

News Media Contacts:

RadioShack Media Relations, +1-817-415-3300, Media.Relations@RadioShack.com
Defense Mobile Corp, Ed Walters, +1-888-370-8747 Ext 1028, ewalters@defensemobile.net

(DGLY) Order From State Police Of Michigan Valued at More Than $1.1M

Inclusion of DVM-800 Increases Total Contract Value by Over 40% to $6.5 Million

(EMBR) Announces That W+B Partners Has Been Retained By New Client

Los Angeles, California (FSCwire) – Embarr Downs, Inc. (OTCQB: EMBR) announced that its subsidiary W+B Partners has been retained by a new client to acquire a shell and provide consulting services after the reverse merger.  W+B Partners will be compensated $100,000 plus a 4.9% position in the Company.  W+B Partners has received $50,000 cash and a note payable for the remaining $50,000.  The 4.9% stake is through a Preferred Stock issuance that may not be converted into Common Stock for 12 months.  W+B Partners acquired an additional 4.5% bring the Company’s total ownership to 9.4%.

About Embarr Downs.  The Company is a holding company that operates through its subsidiaries Embarr Downs of California, SouthCorp Capital, W+B Partners and Tren TV.

Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate.

Contacts:

Embarr Downs, Inc.

Joseph Wade

(949) 461-1471

info@embarrdowns.com

www.embarrdowns.com

(STHC) Announces It Has Acquired Approximately 1.5 Acres

SouthCorp Capital Announces It Has Acquired Approximately 1.5 Acres

Santa Monica, California (FSCwire) – SouthCorp Capital, Inc. (OTCQB: STHC) announced today that the Company acquired approximately 1.5 acres of vacant land in Indiana.  The Company is currently drawing up plans to build an apartment building with up to 32 units.  Construction is expected to begin once the plans have been approved.

The units being planned will be 3 bedroom – 2 bathroom units and are expected to rent for $600-$800 per month.   Based on expected construction costs, the Company expects a yearly ROI of 25-30%.

About SouthCorp Capital.  Southcorp Capital, Inc. is a Delaware corporation. The Company focus is on the acquisition and renovation of single-family and multi-family properties in the U.S with the intent of reselling the property after renovations have occurred.  Our real estate investments are expected to focus properties undervalued and/or in need of some repairs.

Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate.

Contacts:

SouthCorp Capital, Inc.

Joseph Wade

661-418-7842

info@southcorpcapital.com

www.southcorpcapital.com

(SGOC) launches online sales platform on JD.com

HONG KONG, Aug. 28, 2014  — SGOCO Group, Ltd. (Nasdaq: SGOC), (“SGOCO” or the “Company”), a company focused on product design, distribution and brand development in the China display market, today announced a new on-line sales platform on JD.com to accelerate the delivery of high quality service and products. SGOCO takes a significant step towards the development of e-commerce through this arrangement. With the sharing of vision and strengths, the agreement will allow both parties to drive new growth opportunities.

By signing the new distribution agreement, SGOCO agrees to provide the best-priced, exclusive and competitive products to JD.com for online direct sales. The new arrangement enhances the cooperation between these two companies and demonstrates SGOCO’s commitment to establish new distribution channels and its vision of offering customers the latest products to satisfy the demand of online trading platforms.

JD.com is one of the largest Chinese based e-commerce platform and online direct sales company in terms of transaction volume. It was listed on NASDAQ in 2014. According to iResearch, it gained 54.3% market share in Chinese online direct sales market in the second quarter of 2014. Its excellent customer service and high reputation in the industry have earned solid customer base and contributed to the popularity in social network.

Regarding the newly launched sales platform, Mr. David Xu, Director, President and CEO of SGOCO, commented, “SGOCO takes a decisive step further towards the implementation of e-commerce and the alliance is a key strategy for the Company. We are excited to cooperate with JD.com and confident that the positive cooperation can create unique and meaningful new growth opportunities. Developing new distribution channels enables our products to be more accessible to our customers and further expand our customer base.”

He added, “We are constantly looking for potential e-commerce partners and are happy to team up with JD.com, a reliable and progressive company which will support our strategy initiatives. Consumers can enjoy superior online retail experience and comprehensive customer services with the new distribution channel. In line with our transformation plan, we are eager to increase our participation in the e-commerce market in the future.”

About SGOCO Group, Ltd.

SGOCO Group, Ltd. is focused on product design, brand development and distribution in the Chinese display market, including computer monitors, All-In-One (AIO) and Parts-In-One (PIO) computers and application specific products. SGOCO sells its products and services in the China market and abroad. For more information about SGOCO, please visit our investor relations website http://www.sgocogroup.com .

Safe Harbor and Informational Statement

This announcement contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate” or similar expressions, are “forward-looking statements”. Forward-looking statements in this release include, without limitation, the effectiveness of the Company’s multiple-brand, multiple channel strategy and the transitioning of its product development and sales focus and to a “light-asset” model, Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. These forward-looking statements can change as a result of many possible events or factors not all of which are known to the Company, which may include, without limitation, requirements or changes adversely affecting the LCD and LED market in China; fluctuations in customer demand for LCD and LED products generally; our success in promoting our brand of LCD and LED products in China and elsewhere; our ability to have effective internal control over financial reporting; our success in designing and distributing products under brands licensed from others; management of sales trend and client mix; possibility of securing loans and other financing without efficient fixed assets as collaterals; changes in government policy in China; the fluctuations and competition in sales and sale prices of LCD and LED products in China; China’s overall economic conditions and local market economic conditions; our ability to expand through strategic acquisitions and establishment of new locations; compliance with government regulations; legislation or regulatory environments; geopolitical events, and other events and/or risks outlined in SGOCO’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F and other filings. All information provided in this press release and in the attachments is as of the date of the issuance, and SGOCO does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

Kathy Ko
Investor Relations Officer
Tel: +852 2501 0128
US: +1(646) – 5831616 (Voice mail)
Email: ir@sgoco.com

(AGRC) Announces the Sale of 9,428,571 Shares of Its Common Stock

(GYST) Announces Copper Campaign #2 Results

Las Vegas, Nevada (FSCwire) – The Graystone Company (OTC: GYST) announced today that its wholly owned subsidiary, Grupo Mineral Inca, SAC (GMI) has completed the Company’s copper campaign #2 in Peru with the following results.

The company produced and/or sourced 187 tons of copper/gold ore at a total cost of $116.90 per ton. The company sold its copper/gold concentrate equaling $224.59 per ton of ore. The company’s copper campaign #2 produced a net profit of $107.69 per ton of ore processed. Campaign #2 had an increased per ton profit of $31.34 compared to the net profit per ton of $76.35 for campaign #1. GMI’s gross revenue from campaign #2 was $41,998.

As per the terms of the joint venture agreement on its copper claim, the company also recouped its operational costs specific to campaign #2. “Considering this was our second campaign in copper and our first round of bulk ore purchase, were pleased to once again turn a per ton net profit,” said Graystone CEO. “We produced a recoverable amount of gold which was not present in the first campaign. Our experience of conducting a successful campaign mining copper and the purchase of bulk ore has enabled us to become more efficient and profitable in this area of our mining operations.”

Our plan for campaign #3 is to continue mining at our copper claim in Peru and expand our bulk ore purchase program including more gold rich ore purchases. After a brief break for the workers, Campaign #3 is scheduled to start on or about September 15, 2014.

The company also announced today that its gold prospecting teams have identified two new targets on its gold claims. Testing is underway to determine if the company will open up new gold mining camps for these new targets.

A gold update from its Gold claims in Peru and Suriname will be available on or about September 9^th, 2014. The company is currently producing gold weekly via bulk sampling at several of its gold mining camps in Suriname and Peru. Satellite images, claim information and camp/ore processing photos can be found on its website www.graystone1.com and/or octmarkets.com filings and the SEC’s website.

The company has also uploaded to otcmarkets.com lab testing results from samples taken from its ore pile on August 14, 2014.

About The Graystone Company  The Graystone Company, Inc. is a U.S.-based mining and exploration company focused on acquiring and developing gold and other mineral properties. The Company’s strategy is to build value for shareholders by the identification, acquisition and exploration of early-stage properties that show significant potential for the discovery of gold.

Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contacts:

The Graystone Company, Inc.

(702) 289-4827

info@graystonegold.com

www.graystone1.com

(REVI) Expanding Focus on Direct-Mail Division

(NTWK) Signs $16M Contract to Implement NFS Ascent™

Solution to be Deployed Across 5,000+ Concurrent System Users

CALABASAS, Calif., Aug. 27, 2014  — NetSol Technologies, Inc. (Nasdaq:NTWK), a global business services and enterprise application solutions provider, today announced it has signed an agreement valued at more than $16 million to implement NFS Ascent™, the company’s next-generation software platform.

The implementation, with a major multi-finance group in Asia, will fully automate all finance front and back office operations, while managing a portfolio of nearly two million contracts, serving more than 5,000 concurrent users. The name of the client was withheld per a non-disclosure agreement.

“This is a major win for NFS Ascent and we are extremely excited to be the solution partner for such a high volume and iconic finance business,” said Naeem Ghauri, president of global sales for NetSol. “NFS Ascent is designed to improve productivity, performance and responsiveness, while seamlessly integrating into a customer’s current technology framework and infrastructure.”

The implementation is scheduled to be completed within the next 18 months, with the first phase scheduled to go live in February 2015. License and services revenue will generate more than $10 million in revenues. In addition, the five-year cost of ownership, including maintenance and support, brings the contract value to more than $16 million.

About NFS Ascent™

NFS Ascent™ serves asset, auto captive and non-captive businesses globally. Designed as part of a full business platform for maximum flexibility and customization, NFS Ascent can be used in multinational, multi-company, multi-asset, multi-lingual, multi-distributor and multi-manufacturer environments. Each application within NFS Ascent is a complete solution in itself and can be used independently to address specific areas of the leasing/financing cycle – or collectively, as an end-to-end solution, covering the full leasing and finance cycle from quotation origination through end of contract at the retail and wholesale levels. More information about NFS Ascent can be found by visiting: http://ascent.netsoltech.com.

About NetSol Technologies, Inc.

NetSol Technologies, Inc. (Nasdaq:NTWK) is a worldwide provider of global IT and enterprise application solutions. Since its inception in 1995, NetSol has used its BestShoring™ practices and highly experienced resources in analysis, development, quality assurance, and implementation to deliver high-quality, cost-effective solutions. Specialized by industry, these product and service offerings include credit and finance portfolio management systems, SAP consulting and services, custom development, systems integration, and technical services for the global financial, leasing, insurance, energy, and technology markets. NetSol’s commitment to quality is demonstrated by its achievement of the ISO 9001, ISO 27001, and SEI (Software Engineering Institute) CMMI (Capability Maturity Model) Maturity Level 5 assessments, a distinction shared by 162 companies worldwide. NetSol Technologies’ clients include Fortune 500 manufacturers, global automakers, financial institutions, utilities, technology providers, and government agencies. Headquartered in Calabasas, California, NetSol Technologies has operations and offices in Alameda, Adelaide, Bangkok, Beijing, Karachi, Lahore, London, and Riyadh.

To learn more about NetSol, visit www.netsoltech.com.

NetSol Technologies, Inc. Forward-looking Statements

This press release may contain forward-looking statements relating to the development of the Company’s products and services and future operation results, including statements regarding the Company that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words “believe,” “expect,” “anticipate,” “intend,” variations of such words, and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Factors that could affect the Company’s actual results include the progress and costs of the development of products and services and the timing of the market acceptance. The subject Companies expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

(PXBP) and (MPB) Announce Agreement to Merge

MILLERSBURG, Pa. and MINERSVILLE, Pa., Aug. 27, 2014  — Mid Penn Bancorp, Inc. (“Mid Penn”) (Nasdaq:MPB), headquartered in Millersburg, Pennsylvania, and Phoenix Bancorp, Inc. (“Phoenix”) (OTC:PXBP), headquartered in Minersville, Pennsylvania, today announced the signing of a definitive merger agreement which calls for Mid Penn to acquire Phoenix in a transaction valued at approximately $14.5 million. The transaction expands Mid Penn’s footprint in Schuylkill County and into Luzerne County. On a pro forma basis, the consolidated assets of the combined company will be approximately $875 million.

Under the terms of the agreement, shareholders of Phoenix common stock will elect to receive either 3.167 shares of Mid Penn common stock, or $51.60 in cash, subject to an aggregate proration of 80% stock and 20% cash. As of the close of business on August 26, 2014, the per share acquisition price equaled approximately $50.86, or approximately 110 percent of Phoenix’s fully diluted tangible book value per share at June 30, 2014. Phoenix shareholders are anticipated to own approximately 17% of the combined company. Following completion of the merger, Mid Penn expects to remain well-capitalized, and the company expects the transaction will be accretive to earnings per share.

“We are pleased to share this exciting news which serves as a milestone for both institutions,” said Mid Penn President and CEO, Rory G. Ritrievi. “This merger enables Mid Penn and Phoenix’s subsidiary, Miners Bank, to work together to bring the best in banking products and services to the communities in which we operate. By sharing resources and expanding our footprint, we will become stronger and better positioned for continued growth.”

“Joining Mid Penn is the best choice for our shareholders, customers, employees and communities,” said Phoenix President and CEO, George H. Groves. “Merging with Mid Penn will present more opportunities while still allowing us to provide the local and personal service our customers have come to expect. We will be able to leverage the strengths of both banks in order to achieve further growth in our current markets and beyond.”

Mid Penn has proposed that Phoenix’s Board Chairman Vincent J. Land and Board Members Noble C. Quandel, Jr., and Robert Moisey be added to the Board of Mid Penn and Mid Penn Bank upon completion of the merger.

Phoenix Chairman Vincent J. Land commented, “While we are pleased to join forces with a well performing community banking organization like Mid Penn, we are also excited to have the Miners Bank name live on. That name has been serving the good people of Schuylkill and now Luzerne Counties since 1935 and will continue to do so long into the future.”

Subject to customary closing conditions including regulatory and shareholder approvals, the merger is expected to close in the first quarter of 2015. Following completion of the merger of Mid Penn and Phoenix, Phoenix’s subsidiary bank, Miners Bank, will be merged into Mid Penn Bank and will operate as “Miners Bank, a Division of Mid Penn Bank.”

Keefe, Bruyette & Woods, Inc., acted as financial advisor to Mid Penn, and Stevens and Lee, P.C., acted as its legal advisor in the transaction. Griffin Financial Group, LLC, acted as financial advisor to Phoenix, and Bybel Rutledge LLP, acted as its legal advisor.

About Mid Penn

Mid Penn Bancorp, Inc. is a Central Pennsylvania bank holding company with total assets of approximately $736 million as of June 30, 2014. Headquartered in Millersburg, Pa., Mid Penn is the parent company of Mid Penn Bank, serving the community since 1868. Mid Penn Bank has 14 retail locations in Cumberland, Dauphin, Northumberland and Schuylkill Counties. The bank offers a diverse portfolio of products and services to meet the personal and business banking needs of the community. To learn more about Mid Penn Bank, visit www.midpennbank.com.

About Phoenix

Phoenix Bancorp, Inc. is a bank holding company with total assets of approximately $141 million as of June 30, 2014. Headquartered in Minersville, Pa., Phoenix is the parent company of Miners Bank. Serving the community since 1935, Miners Bank provides a complete line of personal and business banking services through its four retail locations in Schuylkill and Luzerne Counties. Additional information is available through the bank’s website at www.theminersbank.com.

Additional Information About the Merger and Where to Find It

In connection with the proposed merger, Mid Penn will file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 to register the shares of Mid Penn common stock to be issued to the shareholders of Phoenix. The registration statement will include a joint proxy statement/prospectus, which will be sent to the shareholders of Mid Penn and Phoenix seeking their respective approvals of the merger. In addition, each of Mid Penn and Phoenix may file other relevant documents concerning the proposed merger with the SEC.

WE URGE INVESTORS AND SECURITY HOLDERS TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE JOINT PROXY STATEMENT/PROSPECTUS INCLUDED WITHIN THE REGISTRATION STATEMENT AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MID PENN, PHOENIX AND THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents, when they become available, through the website maintained by the SEC at www.sec.gov. Free copies of the joint proxy statement/prospectus, when it becomes available, also may be obtained by directing a request by telephone or mail to Mid Penn Bancorp, Inc., 349 Union Street, Millersburg, Pennsylvania 17061, Attention: Investor Relations (telephone: 717-692-7105) or Phoenix Bancorp, Inc., Rockwood Center, 1504 Rt. 61 South, Pottsville, Pennsylvania 17901, Attention: Investor Relations (telephone: 570-544-6438) or by accessing Mid Penn’s website at www.midpennbank.com under “Investors” or Phoenix’s website at www.theminersbank.com under “Phoenix Bancorp.” The information on Mid Penn’s and Phoenix’s websites is not, and shall not be deemed to be, a part of this release or incorporated into other filings either company makes with the SEC.

Mid Penn, Phoenix and their respective directors, executive officers and members of management may be deemed to be participants in the solicitation of proxies from the shareholders of Mid Penn and Phoenix in connection with the transaction. Information about the directors and executive officers of Mid Penn is set forth in the proxy statement for Mid Penn’s 2014 annual meeting of shareholders filed with the SEC on March 27, 2014. Additional information regarding the interests of these participants and other persons who may be deemed participants in the merger may be obtained by reading the joint proxy statement/prospectus regarding the merger when it becomes available.

Caution Regarding Forward-Looking Statements

Statements made in this release, other than those concerning historical financial information, may be considered forward-looking statements, which speak only as of the date of this release and are based on current expectations and involve a number of assumptions. These include statements as to the anticipated benefits of the merger, including future financial and operating results, cost savings and enhanced revenues that may be realized from the merger as well as other statements of expectations regarding the merger and any other statements regarding future results or expectations. Each of Mid Penn and Phoenix intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and is including this statement for purposes of these safe harbor provisions. The companies’ respective abilities to predict results, or the actual effect of future plans or strategies, is inherently uncertain. Factors that could have a material effect on the operations and future prospects of each of Mid Penn and Phoenix and the resulting company, include but are not limited to: (1) the businesses of Mid Penn and/or Phoenix may not be integrated successfully or such integration may be more difficult, time-consuming or costly than expected; (2) expected revenue synergies and cost savings from the merger may not be fully realized or realized within the expected timeframe; (3) revenues following the merger may be lower than expected; (4) customer and employee relationships and business operations may be disrupted by the merger; (5) the ability to obtain required regulatory and shareholder approvals, and the ability to complete the merger on the expected timeframe may be more difficult, time-consuming or costly than expected; (6) changes in interest rates, general economic conditions, legislation and regulation, and monetary and fiscal policies of the U.S. government, including policies of the U.S. Treasury, the Federal Deposit Insurance Corporation and the Board of Governors of the Federal Reserve System; (7) the quality and composition of the loan and securities portfolios, demand for loan products, deposit flows, competition, and demand for financial services in the companies’ respective market areas; (8) the implementation of new technologies, and the ability to develop and maintain secure and reliable electronic systems; (9) accounting principles, policies, and guidelines; and (10) other risk factors detailed from time to time in filings made by Mid Penn with the SEC. Forward-looking statements reflect Mid Penn’s and Phoenix’s management’s analysis as of the date of this release, even if subsequently made available by Mid Penn or Phoenix on their respective websites or otherwise. Mid Penn and Phoenix undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise.

This release shall not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such solicitation would be unlawful.

CONTACT: Rory G. Ritrievi
         President & Chief Executive Officer
         Mid Penn Bancorp, Inc.
         rory.ritrievi@midpennbank.com
         717-692-7103

         George H. Groves
         President & Chief Executive Officer
         Phoenix Bancorp, Inc.
         ggroves@theminersbank.com
         570-544-6438

(VOIS) Creates EEG/BCI Device That Fits In Your Ear

SAN DIEGO, Aug. 27, 2014  — Mind Solutions, Inc. (OTC – VOIS), is pleased to unveil the images of the first mobile EEG / BCI device worn on your ear. Like a common Bluetooth cellular device, the product is worn around the ear, with a single dry sensor receiving EEG signals from within the ear. This creates a very mobile product that is extremely user-friendly.

The Company has secured a patent pending status on the anatomical location of receiving EEG signals on the device from inside the ear and has implemented this technology into a cutting edge design. Raw prototypes have successfully been tested for functionality and ergonomics and The Company expects to receive five final versions for Beta testing within the next few weeks. Once tested successfully, The Company plans to begin tooling for manufacturing.

This mobile EEG device is expected to operate smart phones and computer devices with the power of your mind. As electrical impulses are received, the device translates thoughts into actions on your mobile device or computer.

The Company has recently announced that Joe Abrams, Co-Founder of MySpace parent company has joined our Advisory Board. The Company is working diligently to leverage the contacts and partnerships that Mr. Abrams brings to the table, with a focus on large companies providing world-wide distribution of The Company’s products upon the completion of our EEG micro headset.

Investor Relations – Casey Burt 561-929-2324
Contact@MindSolutionsCorp.com

(QUSA) to Administer Online Field Test for ELPA21 Consortium

APPLE VALLEY, Minn., Aug. 27, 2014  — The English Language Proficiency Assessment for the 21^st Century consortium (ELPA21) has chosen Questar Assessment, Inc. to produce a field test to collect information that will be used to guide the development of its first English Language Proficiency (ELP) Assessment.

ELPA21, a consortium of 11 states — Arkansas, Florida, Iowa, Kansas, Louisiana, Nebraska, Ohio, Oregon, South Carolina, Washington, and West Virginia — is developing this assessment system based on a new set of ELP standards developed in 2013. The new standards were stablished by education and assessment experts at WestEd to assess ELLs’ English language proficiency and correspond to states’ rigorous content standards in English language arts, mathematics and science. ELPA21’s assessment will be used to gauge how students reach these standards. Questar Assessment’s field test will measure the performance of ELLs in grades K–12 in the four domains of reading, writing, listening, and speaking. Scheduled for online administration in February and March 2015 on Questar Assessment’s next generation online delivery platform, the field test will be scored and items analyzed to inform the construction of the ELPA21 assessment used by each state in the consortium during the 2015–16 school year. In addition, technical reports about the field test and standard setting will be submitted to the Council of Chief State School Officers (CCSSO) in the Fall of 2015.

“We’re excited to support ELPA21’s goals to assess and better support learning for English Language Learners,” said Jamie Post Candee, President and Chief Executive Officer of Questar Assessment, Inc. “We’re looking forward to applying our industry-leading, online assessment platform to help advance the ELP assessment for the ELPA21 consortium.”

Questar Assessment brings relevant ELL assessment expertise to the partnership. Previously, it conducted ELL assessment for Florida, Idaho, Michigan, Missouri, Montana, New York, and Utah, and scoring for the University of Michigan.

About Questar Assessment, Inc.

Questar Assessment, Inc. is a leading educational assessment provider for states, schools, and school districts. Headquartered in Minnesota, Questar offers comprehensive custom assessment services—from large-scale statewide assessment programs to alternate, modified, and English language proficiency assessments. Questar provides complete, end-to-end services designed to address all aspects of assessment: from test design, development, calibration, and psychometric services to print production, distribution, scanning, scoring, reporting, and data analysis. Questar also offers customized online testing services to schools and educational entities in the K–12 market. For further information, visit www.QuestarAI.com or call 1-800-800-2598.

About ELPA21

ELPA21 is a consortium of 11 states developing an assessment system to equip English language learners, teachers, and families with the tools and supports students need for college and career readiness. The consortium—Arkansas, Florida, Iowa, Kansas, Louisiana, Nebraska, Ohio, Oregon, South Carolina, Washington, and West Virginia—is basing its assessment system on the new English Language Proficiency Standards, which reflect the recent research and progress made in the study and development of English language proficiency. ELPA21 is collaborating with the Understanding Language Initiative of Stanford University, the National Center for Research on Evaluation, Standards, and Student Testing of the University of California, Los Angeles, and the Council of Chief State School Officers. The Oregon Department of Education is the lead state agency, and CCSSO is the project management partner. Please visit www.elpa21.org for more information.

(SPIN) Peter Dalrymple Joins Spine Pain Management Board

HOUSTON, Aug. 26, 2014  — Spine Pain Management, Inc. (OTCQB:SPIN), a technology-driven, financial services, medical device, and healthcare solution company servicing the multi-billion dollar spine injury sector, today announced the addition of Peter Dalrymple to the Board of Directors. Mr. Dalrymple, who is an investor in SPIN, currently serves as Managing Partner of LPD Investments.

Mr. Dalrymple was one of the co-founders and owners of the Royal Purple Synthetic Lubricants Company, which at the time of its sale in 2012, was one of the largest synthetic lubricants company in North America, with worldwide distribution totaling over 25,000 outlets. While with Royal Purple, he was in charge of Sales and Marketing. After the company was sold to Calumet Specialty Products Partner, a New York Stock Exchange company, for $330,000,000 in July of 2012, Mr. Dalrymple became a very active investor in several companies. He is also a trustee of Norwich University, from which he holds a Bachelor of Science Degree in Engineering Management. He previously served as a Lieutenant with the United States Army Corp. of Engineers.

Already a sizable equity investor in SPIN since mid-2012, Mr. Dalrymple provided a $1 million three year term loan to the Company in August 2012. After recently meeting the two new management additions, Mike Smith and David Spencer, and reviewing the company’s recently reported financial results, Mr. Dalrymple approached the Company with a proposal to facilitate a $2 million revolving line of credit along with extending and reducing the interest on his original note. The company has agreed to the terms and expects the financing to close in one to two weeks. Additionally, Mr. Dalrymple was asked to and has agreed to join the company’s Board of Directors on August 20th.

Mr. Dalrymple stated, “I have had the opportunity to get to know SPIN’s management and have closely followed its progress. While the business model for both the core business and QVH has made a lot of sense, my only real concern was a lack of young and aggressive talent on the management team to spearhead development, sales and marketing, areas close to my heart, as a founding and long time SVP of Sales and Marketing with Royal Purple. With the additions of Messrs. Smith and Spencer, I believe the final ingredients are in place to proudly lend my name, money and expertise to the company.”

William F. Donovan, M.D., CEO of Spine Pain Management: “With the addition of Peter, we now have SPIN’s three largest shareholders on the Board of Directors, including Peter, Jerry Bratton and myself. This should be very comforting to shareholders that their best interests are represented by the Board.”

About Spine Pain Management, Inc:

We are a technology driven, financial services, medical device and healthcare solution company facilitating diagnostic services for patients who have sustained spine injuries resulting from traumatic accidents. We deliver turnkey solutions to spine surgeons, orthopedic surgeons and other healthcare providers that provide necessary and appropriate treatment of musculo-skeletal spine injuries resulting from automobile and work-related accidents. Our financial services help reduce the burden on healthcare providers that provide patients with early-stage diagnostic testing and non-invasive surgical care, preventing many patients from being unnecessarily delayed or inhibited from obtaining needed treatment. We believe that our services and technology brings strong transparency and impartiality to all parties involved in the settlement of patient cases.

Our proprietary medical device called the Quad Video HALO(TM) facilitates the above mentioned transparency and will shortly be available for third party sales.

Additional information about the company, along with a video can be found at its website at www.spinepaininc.com.

Forward-Looking Statements: This press release includes forward-looking statements as determined by the U.S. Securities and Exchange Commission (the “SEC”). All statements, other than statements of historical facts, included in this press release that address activities, events, or developments that the company believes or anticipates will or may occur in the future are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to acquire and develop specific projects, the ability to fund operations, healthcare services demands, changes in healthcare practices, government regulation, and other factors over which the company has little or no control. The company does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the warnings and cautionary statements contained in the company’s recent filings with the SEC.

CONTACT: Company Contact
         Dr. William F. Donovan
         Chairman, President & CEO
         Spine Pain Management, Inc.
         (713) 521-4220

(DDDX) Provides Update to Shareholders

BELLINGHAM WA, United States, via ETELIGIS INC., 08/26/2014 – – 3DX Industries Inc. (OTCQB: DDDX) 3DX Industries Inc., (the Company or 3DX), is pleased to provide an update to its shareholders on current developments. The company continues to produce 3D metal printed parts using the M-FlexTM Metal Printing System manufactured by The ExOne Company. The ExOne Company (ExOne) is a global provider of three-dimensional (“3D”) printing machines and printed products to industrial customers. Current workload consists of proto-type and production run parts for various industries including agriculture, green energy generation, food processing and other industrial components now in use by our clients.

We could not be more pleased with the parts and components produced by the M-FlexTM Metal Printing System and continue to receive very positive feedback from our clients using this process comments 3DX President and CEO Roger Janssen. Now that word is out on the capabilities of this technology, we are seeing many new clients come in and discuss their projects with us, its a very exciting time for the company adds Mr. Janssen.

3DXs M-FlexTM metal printing system from ExOne, uses an additive manufacturing process, otherwise known as three-dimensional printing, or 3DP, which materializes an objector mold for an objectlayer by layer out of powdered material, a chemical binder and a digital file(1). The process is also referred to as Binder Jetting Technology. The ability to offer clients the option of manufacturing their products using Binder Jetting Technology provided by the M-FlexTM metal printing system will not only save on production costs but also will save time on the engineering and evaluation aspects relative to new and redesigned product manufacturing. The ability to make immediate changes within a CAD file, and have those changes sent directly to the print floor will change the way companies bring products to market.

The company is also working towards increasing its capacity for traditional manufacturing processes in order to supplement cash flow opportunities and support its growing 3D Metal printing market. Many of our new clients looking at the 3D Metal Printing process have traditional manufacturing opportunities that we can satisfy, along with offering them a 3D Metal printing solution states Mr. Janssen.

About the Company:

3DX Industries, Inc. is focused on the additive metal manufacturing segment within the manufacturing industry. 3DX has the capability of manufacturing a wide variety of products using its 3D metal printing system, 3D composite printing as well as more traditional methods of precision manufacturing. 3DX offers additive and traditional manufacturing services as well as product design, engineering and assembly services to its customers.

Visit the 3DX Industries, Inc. web site at www.3dxindustries.com. Information included on the Company’s website is not incorporated herein by reference or otherwise.

About the ExOne Company

For more information about the ExOne Company please visit their website at www.exone.com

(1) The ExOne Company www.exone.com – http://exone.com/en/materialization/what-digital-part-materialization

Safe Harbor

3DX encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by3DX Industries, Inc. that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the company’s business prospects and performance. The company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The company does not undertake any responsibility to update the forward-looking statements contained in this release.

CONTACT:

For additional information please contact:

3DX Industries, Inc.

6920 Salashan Parkway Suite D-101

Ferndale WA 98248

Telephone: 360-244-4339

Email: info@3dxindustries.com

(GENE) Announces Further Patent Success in USA

North Carolina Court Denies Motion to Dismiss, Brought by GlaxoSmithKline, LLC

(GAIMF) DealNet Secures Early Start Letter To Commence BPO Services

DealNet Capital Corp.
Bob Cariglia
President and CEO
+1-416-806-8816
bcariglia@dealnetcapital.com

First Canadian Capital Corp.
Eric Balog
416-742-5600 or 1-866-580-8891
ext 235
info@firstcanadiancapital.com

First Canadian Capital Corp.
Dan Boase
416-742-5600 or 1-866-580-8891
ext 232
info@firstcanadiancapital.com

(CHMD) MyANGKASA Holdings Appoints Clixster

SELANGOR, Malaysia, Aug. 26, 2014  — MyANGKASA Holdings Sdn Bhd (MyANGKASA), a wholly owned subsidiary of the National Cooperative Organisation (ANGKASA) of Malaysia, has appointed Clixster Mobile Sdn Bhd, a Malaysian subsidiary of Clixster Mobile Group Inc. (Stock Code: CHMD, U.S.:OTC) (Clixster Mobile Group), as the supplier and administrator of the former’s membership card program for the entire members of ANGKASA.  ANGKASA currently has around 8.4 million members registered under more than 11,000 cooperatives all over the country.

In line with this appointment, Clixster Mobile Group will be working together with Clix2Pay in payment terminal program and development of  a central database system for updating of data and profiles of cooperatives and their members on behalf of ANGKASA.

The ANGKASA’s membership card, envisaged to be issued in November 2014, is a multi purpose smart card that will be bundled with Umrah Fund and a prepaid/postpaid Clixster Mobile’s SIM card.

Subsequently, MyANGKASA and Clixster Mobile Group will tie up with a local bank for the issuance of bank card to ANGKASA’s members with payment facilities under Mastercard or Visa which will be acceptable at more than 28 million premises globally.

In addition to being an identification of membership in a cooperative registered with the Malaysia Cooperative Commission, the membership card also acts as payment instrument with ease and efficient at many selected business premises in the country.

Other features to be incorporated to the card are loyalty programs, MyKifayah-Clixster package on death burial benefits and other value-added services for the cardholders.

According to the President of ANGKASA who is also the Chairman of MyANGKASA HOLDINGS SDN BHD, this collaboration between MyANGKASA, Clixster Mobile Group and the prospective Bank will give an impetus to the benefits and offerings for the members of ANGKASA.

By establishing the ANGKASA’s card membership program, the offerings from all business partners of MyANGKASA can also be standardized into the central database system.

The image accompanying this release can be viewed at:
http://mrem.bernama.com/photo/22858.jpg

Caption: En Azlan Khamis, Group Chief Executive Officer Clixster Mobile (Two From Left) Reacting To Reporter During The Press Conference Of Pre-Launch ‘MyANGKASA Membership Card’ In Kelana Jaya. Also Presence The President Of ANGKASA, Datuk Fatah Abdullah (Left), Group Chief Development Officer Of Clixster Mobile, En Reza Shah Hussein (Three From Left) And Syed Ahmad Fuad Syed Abdullah, Chief Executive Officer Of Clix2Pay.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Name: Mr Asrul Nahar Razak
Tel: +6013 209 1757
Email: asrul@clixster.net

Name: Mr Suhaimi Rozali
Tel: +6011 2211 3100
Mobile: suhaimi@clixster.net

(KITM) Advances Mobile Video Advertising with Propel ‘Forward’ Technology Release

Brands Engage Multi-Screen Targeted Audiences with Advanced Metrics

JERSEY CITY, N.J., Aug. 26, 2014  — Kitara Media (OTCBB: KITM), a leading digital media and technology company providing video solutions to advertisers, digital marketers and publishers, today announced its release of Propel Forward, an expanded set of offerings for mobile and multi-screen video advertising.

“According to the IAB BI Intelligence Report, with the exception of mobile advertising, online video is growing faster than most other advertising mediums. Propel Forward combines the power of video and mobile in one platform,” said Bob Regular, CEO of Kitara Media. “By using Propel Forward, publishers gain a simple solution that provides video content and advertising across all screens and brands gain access to a turnkey advertising solution that offers cross screen advantages and drives audience engagement. We have invested in our technology platform to give advertisers the ability to create diversified campaigns aligned with brand objectives.”

Propel Forward is a video advertising solution designed to automate and manage the real time bidding process matching advertising inventory with target audiences delivered by publishers. Automating brand performance, Propel Forward integrates proprietary and third party technology systems and measurement to enable viewability measurement, ad safety firewalls, and advanced ad performance measurement. Benchmarking performance and safety, Propel Forward ensures quality brand metrics with targeted campaigns across the Kitara Media portfolio of owned and operated sites combined with the Propel Marketplace of syndicated publishers.

About Kitara Media

Kitara Media is a leading digital media and technology company providing video solutions to advertisers, digital marketers and publishers. With nearly 500 million monthly video ad views, Kitara Media delivers strong engagement for advertisers, high revenues for publishers, as well as improved user experience with PROPEL+, an internally developed proprietary video ad technology platform. Kitara Media owns and operates several online media sites including Healthguru.com and Adotas.com. The company is headquartered in Jersey City, NJ. For more information visit http://www.kitaramedia.com.

Forward-Looking Statements:

Certain information and statements contained in this press release, including those statements that are not statements of historical fact, are forward-looking statements within the meaning of federal securities laws. These statements may be identified, without limitation, by the use of forward-looking terminology such as “anticipates”, “expects,” “will” or comparable terms or the negative thereof. Such statements are based on management’s current estimates, assumptions that management believes to be reasonable, and currently available competitive, financial, and economic data as of the date hereof and we undertake no obligation to update any such statements to reflect subsequent changes in events or circumstances. Forward-looking statements are inherently uncertain and subject to a variety of events, factors and conditions, many of which are beyond the control of Kitara Media and not all of which are known to Kitara Media, including, without limitation those risk factors described from time to time in Kitara Media’s reports filed with the SEC.  Among the factors that could cause actual results to differ materially are Kitara Media’s: loss of key advertising customers; inability to acquire new advertising customers; inability to expand its video content library; inability to protect its intellectual property; inability to comply with the covenants in its credit facility; inability to obtain necessary financing or enter into equity arrangements with existing or new institutional shareholders; inability to execute its acquisition strategy; inability to effectively manage its growth; failure to effectively integrate the operations of acquired businesses; competition; loss of key personnel; increases in costs of operations; continued compliance with government regulations; and general economic conditions.

(ADXS) and Merck Form Collaboration

PRINCETON, N.J., Aug. 25, 2014  — Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s investigational anti PD-1 antibody, pembrolizumab. The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.

Both ADXS-PSA and pembrolizumab are investigational members of a new class of cancer treatments known as immunotherapies that are designed to enhance the body’s own defenses in fighting cancer. Preclinical evidence suggests that Advaxis Lm-LLO immunotherapies in combination with a PD-1 inhibitor may lead to an enhanced anti-tumor immune response.

“We are excited to be working with Merck. Equally as exciting is the combination potential of our Lm-LLO immunotherapy with Merck’s anti-PD-1 immune checkpoint inhibitor,” commented Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. “We believe the combination of Advaxis Lm-LLO cancer immunotherapies and checkpoint inhibitors holds significant promise for the treatment of prostate and other cancers.”

Under the terms of the agreement, Advaxis and Merck will collaborate to evaluate the ADXS-PSA/pembrolizumab combination as a treatment for prostate cancer. The Phase 1 part of the trial is designed to establish a recommended dose regimen for ADXS-PSA alone and combined with pembrolizumab, and the Phase 2 portion will assess the safety and efficacy of the combination. Advaxis will sponsor and fund the study and Merck will provide pembrolizumab. The companies will collaboratively oversee the conduct of the study, which is planned to begin in early 2015. Results from the study will be used to determine the path for further clinical development of the combination.

“Collaborations such as this are an integral part of Merck’s strategy to evaluate the potential of pembrolizumab in multiple combinations for a broad range of cancers,” said Dr. Eric Rubin, vice president Oncology, Merck Research Laboratories. “We look forward to working with Advaxis to evaluate this novel investigational combination immunotherapy for the treatment of advanced prostate cancer.”

About Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer. Prostate cancer is the second leading cause of cancer death in men, behind only lung cancer. One man in six will get prostate cancer during his lifetime, and one man in 36 will die of this disease.

About ADXS-PSA

ADXS-PSA is an Lm-LLO immunotherapy that is designed to target the PSA antigen associated with prostate cancer. ADXS-PSA secretes the PSA antigen, fused to the powerful immunostimulant tLLO, directly inside the antigen presenting cells that are capable of driving a cellular immune response to PSA expressing cells. The Advaxis approach is also designed to inhibit the Treg and MDSC cells that contribute to immunologic tolerance of prostate cancer. In preclinical analysis, ADXS-PSA inhibits the immunosuppression caused by Treg and MDSC cells localized inside tumors that we believe promotes immunologic tolerance of prostate cancer.

About Pembrolizumab

Pembrolizumab (MK-3475) is an investigational, humanized, monoclonal antibody against PD-1 designed to reactivate anti-tumor immunity. Pembrolizumab exerts dual ligand blockade of the PD-1 pathway by inhibiting the interaction of PD-1 on T cells with its ligands PD-L1 and PD-L2.

Pembrolizumab is currently being evaluated across more than 30 types of cancers, as monotherapy and in combination. It is anticipated that by the end of 2014, the pembrolizumab development program will grow to more than 24 clinical trials, enrolling an estimated 6,000 patients at nearly 300 clinical trial sites worldwide. For information about Merck’s oncology clinical studies, please visit http://www.merck.com/clinical-trials/index.html.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform intended to redirect the immune system to kill cancer. The Advaxis Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and MSDCs, that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’s lead immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2014 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis is planning to evaluate the combination of ADXS-HPV with an anti-PD-L1 immune checkpoint inhibitor in HPV-associated cancers.

Advaxis’s second immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis is planning to file an IND with the FDA and initiate a Phase 1-2 clinical study with ADXS-PSA. Advaxis is also developing ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is pursuing a clinical program in pediatric osteosarcoma and has licensed ADXS-cHER2 and three other immunotherapy constructs to a major animal-health company. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers.

For more information please visit www.advaxis.com or connect with us on

• Facebook: https://www.facebook.com/advaxisinc
• Twitter: https://twitter.com/Advaxis
• LinkedIn: http://www.linkedin.com/company/advaxis-inc.
• Google+: https://plus.google.com/b/115126287957745987074/115126287957745987074/posts

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis’s ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis’s proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’s SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

CONTACT: Advaxis Contact:
         Lisa Caperelli
         Senior Director of Investor Relations and
         Corporate Communications
         Advaxis, Inc.
         caperelli@advaxis.com
         215.206.1822

         Media Contact:
         Tiberend Strategic Advisors, Inc.
         Amy S. Wheeler
         awheeler@tiberend.com
         646.362.5750

(MREE) & American National Bankshares Announce Agreement to Merge

(MYEC) Signs Agreement With MonthlyFilterClub.Com

(KITE) Announces Patients With Aggressive Non-Hodgkin’s Lymphoma Experience Positive Results

Phase 1-2a Clinical Trial Highlights:

• 12 of 13 Total Evaluable Patients with Advanced B Cell Malignancies Had Complete Remissions (8 Patients) or Partial Remissions (4 Patients) Resulting in a 92% Objective Response Rate
  
• 4 of 7 Evaluable Patients with Chemotherapy-Refractory Diffuse Large B-cell Lymphoma (DLBCL) Achieved Complete Remissions, 3 of Which Are Ongoing and 1 of Which Is Ongoing after 22 Months
  
• The Results Have Been Published in the August 25, 2014 Issue of the American Society of Clinical Oncology’s (ASCO) Journal of Clinical Oncology
  
• The Results Support Kite’s Plan to File an Investigational New Drug Application (IND) in the Fourth Quarter of 2014 to Initiate a Clinical Trial of Kite’s Lead CAR-Based Product Candidate, KTE-C19, in Patients with DLBCL

SANTA MONICA, Calif., Aug. 25, 2014  — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin’s lymphoma with an anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Kite’s most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient’s T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.

The findings from an ongoing Phase 1-2a clinical trial funded by Kite and conducted by the Surgery Branch of the National Cancer Institute (NCI) demonstrated that in 12 out of 13 evaluable patients with advanced B-cell malignancies, administration of anti-CD19 CAR T cells resulted in complete remission in eight patients and partial remission in four patients, representing an overall objective response rate of 92%. Of seven evaluable patients with chemotherapy-refractory DLBCL, four achieved complete remission, three of which are ongoing with durations ranging from 9 to 22 months. These findings are being published in an article titled, “Chemotherapy-refractory Diffuse Large B-cell Lymphoma and Indolent B-cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor,” DOI: 10.1200/JCO.2014.56.2025, which is appearing in the August 25, 2014 issue of the American Society of Clinical Oncology’s Journal of Clinical Oncology.

Kite and the Surgery Branch of the NCI, led by Steven A. Rosenberg, M.D., Ph.D., are collaborating under a Cooperative Research and Development Agreement (CRADA) for the research and development of eACT™ based product candidates for the treatment of multiple cancer indications. The reported Phase 1-2a clinical trial is being conducted at the NCI with Dr. Rosenberg serving as principal investigator. Additional authors of the published study include James N. Kochenderfer, M.D., who presented earlier data for the NCI from the trial at the 55th American Society of Hematology (ASH) Annual Meeting in December 2013.

David Chang, M.D., Ph.D., Kite Pharma’s Executive Vice President, Research and Development, and Chief Medical Officer, commented, “To date, Kite and the NCI have conducted an extensive program to investigate personalized T cell immunotherapies for blood cancers and solid tumors, including in patients with refractory DLBCL. Both the high overall response rate and the durability of the complete remissions are noteworthy, and we believe our anti-CD19-CAR T cell approach holds great potential for the treatment of B cell malignancies, including those with aggressive, resistant disease for which there are no viable treatment options.”

Ronald Levy, M.D., Professor of Medicine, Director of the Lymphoma Program and Former Chief of the Division of Oncology at Stanford University and member of Kite’s Scientific Advisory Board, commented, “I have been impressed by the results reported and updated from Dr. Rosenberg’s group at the NCI. Particularly compelling are the frequency and the duration of the responses obtained in the difficult-to-treat patient population with relapsed, refractory lymphomas.” Dr. Levy serves as a consultant to Kite and is helping to guide the Company in their upcoming clinical trials.

“We are greatly encouraged by the strong results we have seen from our joint lead clinical program with the NCI,” commented Arie Belldegrun, M.D., FACS, Kite’s President and Chief Executive Officer. “Based on this substantial progress, Kite plans to file an IND in the fourth quarter of this year to initiate a Phase 1-2 single-arm multicenter clinical trial of KTE-C19 in patients with DLBCL who have failed two or more lines of therapy. We are excited to advance this promising therapy and anticipate commencing patient enrollment in our DLBCL clinical trial in the first half of 2015.”

Key Study Findings

The published clinical trial results relate to patients in the second cohort in the NCI’s Phase 1-2a clinical trial of anti-CD19 CAR T cell therapy. The second cohort consists of 15 patients, including two retreated patients from a prior cohort, with advanced B cell malignancies, of which 13 were evaluable for responses, including seven with chemotherapy-refractory DLBCL.

Patients received a conditioning regimen of chemotherapy (cyclophosphamide and fludarabine) followed one day later by a single infusion of anti-CD19-CAR T cells. The CAR-expressing T cells were produced from each patient’s own peripheral blood mononuclear cells (PBMCs), modified using a gammaretroviral vector encoding the CAR, as well as a CD28 costimulatory moiety.

Of the seven evaluable chemotherapy-refractory DLBCL patients, six showed a response (four complete remissions and two partial remissions), and one had stable disease.

Duration of ongoing complete responses ranged from 9 to 22 months in patients with chemotherapy-refractory DLBCL and from 11 to 23 months in the patients with either chronic lymphocytic leukemia (CLL) or indolent lymphoma. Pursuant to the study protocol, patients are continuing to be monitored for duration of response. Updated results will be reported at the appropriate peer-reviewed forum.

Summary of Efficacy Findings:

(1) Includes one patient with DLBCL that transformed from chronic lymphocytic leukemia, and three patients with primary mediastinal B cell lymphoma, a subtype of DLBCL.

As seen in other studies, infusion of anti-CD19 CAR T cells was associated with significant, acute toxicities, including fever, low blood pressure, focal neurological deficits, and delirium.

About Kite Pharma

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system’s ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications.  Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success and timing of the ongoing and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation and receipt of preliminary data for our clinical trial of KTE-C19; the ability and willingness of the NCI to continue research and development activities relating to eACT™ pursuant to the CRADA; our expectations regarding the clinical effectiveness and safety of our product candidates and results of the NCI’s clinical trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates and advancing a clinical trial of KTE-C19; and our ability to protect our proprietary technology and enforce our intellectual property rights. Various factors may cause differences between Kite’s expectations and actual results as discussed  in greater detail under the heading “Risk Factors” in the registration statement on Form S-1 (commission file number 333-196081), which was declared effective by the Securities and Exchange Commission (SEC) on June 19, 2014.  Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CONTACT: Kite Contact:
         Cynthia M. Butitta
         Chief Financial Officer and Chief Operating Officer
         310-824-9999

         For Media: Justin Jackson
         For Investor Inquiries: Kimberly Minarovich
         Burns McClellan
         (212) 213-0006
         jjackson@burnsmc.com
         kminarovich@burnsmc.com

(TRLR) Iron-Gold-Platinum Project Interest Reverts Back to the Property Vendor

(MCET) Granted U.S. Patent On Virus Infection/Cancer Therapeutics

WOONSOCKET, R.I., Aug. 25, 2014  — MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer.  These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity, and the ability to present peptide antigens to immune cells resulting in protective anti-tumoral and anti-viral immunity.

In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal’s immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity.  Tumor rejection and protection against similar and new tumor variants was found to also be associated with specific, overall expansion of cytokine producing cells.  This finding indicates a broadening of the repertoire of anti-tumor immune cells and the development of immune memory in the animal.

Mice immunized with MCT-465 and MCT-475 resulted in the priming of an immune response capable of limiting the replication of virus subsequent to further virus infectious challenge.  During viral infection, specific immune system cells begin to proliferate and differentiate which defines the adaptive immune response to the infection.  In mouse models, administration of MCT-465 and MCT-475 greatly enhanced the generation of interferon gamma (IFNγ) and interleukin-2 (IL-2) producing virus antigen-specific T-cells resulting in significantly reduced virus levels present in the animal.

MultiCell is developing MCT-465 and MCT-475 for the treatment of hepatitis B virus infection and hepatitis C virus infection, and for the treatment of certain cancers.

Chronic hepatitis B and chronic hepatitis C virus infection are recognized as major factors worldwide that increase the risk of hepatocellular carcinoma.  According to the U.S. National Cancer Institute (NCI), chronic hepatitis B virus infection and chronic hepatitis C virus infection account for about 30% to 40% of all reported USA cases of hepatocellular carcinoma.

Treatment of hepatocellular carcinoma, the most common form of primary liver cancer, represents a major unmet medical need.   Hepatocellular carcinoma is a leading cause of cancer death worldwide, and is the fourth most common cancer in the world.  Over 1 million cases of hepatocellular carcinoma are reported annually worldwide.  Current approaches for treatment of hepatocellular carcinoma are of limited efficacy.  According to the NCI, only 16% of patients diagnosed with primary liver cancer survive longer than 5 years.

MultiCell is also developing MCT-485, a very small dsRNA therapeutic, thought to target cancer by delivering a cytotoxic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells.  MCT-485 appears to have no effect on cells not directly involved in the process of relapse, progression and metastasis of cancer.  MCT-485 appears to exert a preferential biological activity on liver cancer cells while showing no effect on normal liver cells.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of primary multiple sclerosis-related fatigue and cancer.  For more information about MultiCell Technologies, please visit http://www.multicelltech.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell’s expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”).  These statements are often, but not always, made through the use of words or phrases such as “believe”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “plan”, “forecast”, “could”, and “would”. MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell’s report on Form 10-K for the fiscal year ended November 30, 2013, and all of MultiCell’s quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

(TAST) to Purchase 64 BURGER KING® Restaurants in Tennessee, Indiana and Illinois

Carrols Restaurant Group, Inc. (“Carrols” or the “Company”) (Nasdaq:TAST) today announced that on August 22, 2014 it signed definitive agreements to purchase 64 BURGER KING® restaurants from certain subsidiaries of Heartland Food LLC for a total cash purchase price of approximately $18.0 million excluding inventory. The restaurants to be acquired are located in or around the following markets: Nashville, TN (27 restaurants), Springfield, IL (11 restaurants), Terre Haute, IN (15 restaurants), Evansville, IN (7 restaurants), and other nearby markets (4 restaurants).

Daniel T. Accordino, the Company’s Chief Executive Officer said, “The consummation of this transaction will expand our footprint to a number of markets contiguous to our existing operations and is consistent with our stated strategy to enhance shareholder value through our expanding ownership within the BURGER KING® system. Since our stock offering earlier this year we have completed the acquisition of 29 BURGER KING® restaurants, and the expected closing of this transaction will bring our total 2014 acquisitions to almost 100 restaurants. We also continue to evaluate additional opportunities.”

The transaction is subject to certain closing conditions including satisfactory completion by the Company of due diligence and other customary closing conditions. In conjunction with the transaction, Burger King Corporation has also agreed to make a cash payment to Heartland at closing based on Carrols’ commitment to remodel 46 of the restaurants. Closing is expected to occur in late September or early October.

About the Company

Carrols Restaurant Group, Inc. is the largest BURGER KING^® franchisee in the world with 583 restaurants as of August 22, 2014 and has operated BURGER KING® restaurants since 1976. For more information on Carrols, please visit the company’s website at www.carrols.com.

Forward-Looking Statements

Except for the historical information contained in this news release, the matters addressed are forward-looking statements. Forward-looking statements, written, oral or otherwise made, represent Carrols’ expectation or belief concerning future events. Without limiting the foregoing, these statements are often identified by the words “may”, “might”, “believes”, “thinks”, “anticipates”, “plans”, “expects”, “intends” or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such statements reflect management’s current views with respect to future events and are subject to risks and uncertainties, both known and unknown. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. Investors are referred to the full discussion of risks and uncertainties as included in Carrols’ filings with the Securities and Exchange Commission.

(ASTM) Ixmyelocel-T Shown To Reduce Incident Rates, Ischemic Dilated Cardiomyopathy

Results From Phase 2a IMPACT-DCM and Catheter-DCM Studies Published in Circulation Research

ANN ARBOR, Mich., Aug. 22, 2014  — Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that results from the company’s Phase 2a clinical studies of ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM) were published in the peer-reviewed journal Circulation Research. In an article entitled “Safety and Efficacy of Ixmyelocel-T: An Expanded, Autologous Multi-Cellular Therapy, in Dilated Cardiomyopathy,” results showed that treatment with ixmyelocel-T reduced the incidence of major adverse cardiovascular events (MACE) in patients with ischemic DCM.

In two separate open-label studies, a total of 61 patients were randomized and 59 were treated or received standard of care. The combined results among ischemic DCM patients demonstrated that patients treated with ixmyelocel-T experienced fewer MACE events during follow up compared to control patients. Heart failure (HF) exacerbation was the most common MACE. Relative to the control patients, ischemic DCM patients treated with ixmyelocel-T also experienced an improvement in symptoms as measured by the New York Heart Association classification system, a six-minute walk test, and the Minnesota Living with Heart Failure Questionnaire. Similar benefits were not observed in the non-ischemic population.

“The publication of results from the two Phase 2a trials in a peer-reviewed journal is further validation that the available evidence supports continued development of ixmyelocel-T as a treatment for patients with ischemic dilated cardiomyopathy. We currently are enrolling a larger, Phase 2b trial and hope to replicate these very promising results. People living with ischemic DCM are often severely compromised and have very limited treatment options available, so these results are especially encouraging,” said Dave Recker, M.D., Aastrom’s chief medical officer.

Ixmyelocel-T is a patient-specific, expanded multicellular therapy manufactured from the patient’s own bone marrow using Aastrom’s proprietary, highly automated, fully closed cell-processing system. This process selectively expands the population of mesenchymal stromal cells and alternatively activated macrophages, which are responsible for production of anti-inflammatory and pro-angiogenic factors known to be important for repair of damaged tissue.

“Based upon these results, we see great promise in the use of ixmyelocel-T to treat dilated cardiomyopathy and are working aggressively to advance this development program to the final stages of clinical research and regulatory review,” Dr. Recker added. “As recently announced, we are on pace to enroll 108 patients by year end in the Phase 2b ixCELL-DCM clinical trial of ixmyelocel-T for the treatment of advanced heart failure due to DCM.”

About Aastrom Biosciences

Aastrom Biosciences is the leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit Aastrom’s website at www.aastrom.com.

The Aastrom Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3663

This document contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding the commercial potential of our products and growth in revenues, intended product development, clinical activity timing, and objectives and expectations regarding the business opportunity described herein, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “we believe,” “we intend,” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “potential,” “could,” “may,” or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements, the availability and allocation of resources among different potential uses, estimating the commercial potential of our products and product candidates and growth in revenues, market demand for our products, and our ability to supply or meet customer demand for our products. These and other significant factors are discussed in greater detail in Aastrom’s Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission (“SEC”) on March 13, 2014, Quarterly Reports on Form 10-Q and other filings with the SEC. These forward-looking statements reflect management’s current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

CONTACT: Media contact:
         David Salisbury
         Berry & Company
         dsalisbury@berrypr.com
         (212) 253-8881

         Investor contact:
         Chad Rubin
         The Trout Group
         crubin@troutgroup.com
         (646) 378-2947

(CCIH) to Participate in Morgan Stanley Flagship China Internet, E-Commerce Conference

BEIJING, Aug. 22, 2014  — ChinaCache International Holdings Ltd. (“ChinaCache” or the “Company”) (Nasdaq:CCIH), the leading total solutions provider of Internet content and application delivery services in China, today announced that it will participate in Morgan Stanley Flagship China Internet & E-Commerce Conference on Monday, August 25, 2014, at the Four Seasons Hotel in Beijing, China. Management is scheduled to present at 12:30 pm local time on August 25, 2014.

Management will meet with institutional investors throughout the event. For additional information, please contact the institutional sales representative at Morgan Stanley.

About ChinaCache

ChinaCache International Holdings Ltd. (Nasdaq:CCIH) is the leading total solutions provider of Internet content and application delivery services in China. As a carrier-neutral service provider, ChinaCache’s network in China is interconnected with networks operated by all telecom carriers, major non-carriers and local Internet service providers. With more than a decade of experience in developing solutions tailored to China’s complex Internet infrastructure, ChinaCache is a partner of choice for businesses, government agencies and other enterprises to enhance the reliability and scalability of online services and applications and improve end-user experience. For more information on ChinaCache, please visit ir.chinacache.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the outlook for the third quarter of 2014 and quotations from management in this announcement, as well as ChinaCache’s strategic and operational plans, contain forward-looking statements. ChinaCache may also make written or oral forward-looking statements in its reports filed or furnished to the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statements, including but not limited to the following: the Company’s goals and strategies, expansion plans, the expected growth of the content and application delivery services market, the Company’s expectations regarding keeping and strengthening its relationships with its customers, and the general economic and business conditions in the regions where the Company provides its solutions and services. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and ChinaCache undertakes no duty to update such information, except as required under applicable law.

CONTACT: For investor and media inquiries please contact:

         Mr. David She
         Investor Relations
         ChinaCache International Holdings
         Tel: +86 (10) 6408 5307
         Email: ir@chinacache.com

         Mr. Glenn Garmont or Mr. Don Markley
         The Piacente Group | Investor Relations
         Tel: +1 212-481 2050
         Email: chinacache@tpg-ir.com

(SPPR) Announces Sale of Stone Mountain Savannah Suites

(EMITF) Announces Effectiveness of Reverse Share Split

Elbit Imaging Ltd. (“EI” or “Company“) (NASDAQ GSM: EMITF) announced today that the previously announced one-for-twenty reverse split of the Company’s ordinary shares became effective at 5:00 p.m. (New York time) on Thursday, August 21, 2014 and that the shares commenced trading on a reverse split-adjusted basis upon the open of trading on the NASDAQ Global Select Market on Friday, August 22, 2014. With respect to the Tel Aviv Stock Exchange, the shares will commence trading on a reverse split-adjusted basis upon the open of trading on Sunday, August 24, 2014.

As part of the reverse share split and pursuant to the approval of the Company’s shareholders, on August 21, 2014 the Company’s Memorandum and Articles of Association were amended to reduce the Company’s authorized share capital from 700,000,000 ordinary shares, no par value, to 35,000,000 ordinary shares, no par value.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial and Entertainment Centers – Initiation, construction and sale of shopping and entertainment centers and other mixed-use real property projects, predominantly in the retail sector, located in Central and Eastern Europe and in India, primarily through its subsidiary Plaza Centers N.V. In certain circumstances and depending on market conditions, we operate and manage commercial and entertainment centers prior to their sale; (ii) Hotels – Hotel operation and management; (iii) Medical Industries – (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; (iv) Residential Projects – Initiation, construction and sale of residential projects and other mixed-use real property projects, predominately residential, located primarily in India; (v) Fashion Apparel – Distribution and marketing of fashion apparel and accessories in Israel.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as “believe,” “would,” “expect,” “intend,” “estimate” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2013, under the caption “Risk Factors.” Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.

For Further Information:

Company Contact:
Ron Hadassi
Chairman of the Board of Directors
Tel: +972-3-608-6048
ron@elbitimaging.com